Enlivex Therapeutics receives $1M grant from IIA for sepsis related programs
Enlivex Therapeutics announced that the Israel Innovation Authority, or IIA, selected the company's clinical program for prevention of cytokine storms and organ dysfunction associated with sepsis to receive a non-dilutive grant of approximately $1M for 2019. Enlivex is eligible to receive additional grants from the IIA for this clinical program in 2020 and 2021, subject to certain terms and conditions. To date, Enlivex has received a total of approximately $4.2M of grants from the IIA. Enlivex is currently planning to initiate a Phase II trial of ALLOCETRATM studying the prevention of cytokine storms and organ dysfunction associated with sepsis and is currently planning a Phase II/III trial of ALLOCETRATM studying the prevention of complications post bone-marrow transplantations for early 2020.